QED Therapeutics Stock

Precision medicine for FGFR-driven disorders

Sign up today and learn more about QED Therapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About QED Therapeutics Stock

QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Their lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. They plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.

Investors

Funding History

January 2018$65.0M

Management

President

Neil Kumar

Chief Revenue Officer

Curtis Scribner

Press

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 300K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo